Amarin Corp. (AMRN) announced a $100 million non-equity financing after the bell Thursday with an investment fund managed by Pharmakon Advisors. Amarin is continuing its preparations to commercialize Vascepa capsules with the hiring of a sales force in the United States. The stock is now down 2.30 on 679K shares.
Amarin traded in a range for the majority of Thursday's session and closed down by 0.09 at $11.95. The stock finished near the middle of a 2-month range.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org